A multicenter, randomized, double-dummy, placebo and active-controlled study to assess the safety, tolerability and effect of taspoglutide on glycemic control compared to sitagliptin and placebo in patients with type II diabetes mellitus inadequately controlled with metformin.

Trial Profile

A multicenter, randomized, double-dummy, placebo and active-controlled study to assess the safety, tolerability and effect of taspoglutide on glycemic control compared to sitagliptin and placebo in patients with type II diabetes mellitus inadequately controlled with metformin.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Taspoglutide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EMERGE-4; T-EMERGE-4
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2010 Results were repoted at the 46th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top